COVID-19 therapy and vaccination: a clinical narrative review

Keyphrases

• Acute Respiratory Distress Syndrome 33%
• Anakinra 33%
• Anti-inflammatory Agents 33%
• Anticoagulant Therapy 33%
• Antimicrobial Therapy 33%
• Clinical Benefit 33%
• Clinical Narratives 100%
• Convalescent Plasma 33%
• COVID-19 33%
• COVID-19 Treatment 100%
• COVID-19 Vaccination 100%
• Critically Ill 33%
• Cytokine Storm 33%
• Eculizumab 33%
• Health Problems 33%
• Hospitalized Patients 33%
• Host Immune Response 33%
• Hydroxychloroquine 33%
• IgG1 Monoclonal Antibody 33%
• Immune Response 33%
• Immunoglobulin 33%
• Immunomodulatory Therapy 66%
• In-hospital Mortality 33%
• Inflammatory Response 33%
• Inpatient Hospitals 33%
• Length of Hospital Stay 33%
• Medical Community 33%
• Moderate to Severe 33%
• Multiple Organ Failure 33%
• Narrative Review 100%
• Postdischarge Period 33%
• Remdesivir 33%
• SARS-CoV-2 Infection 33%
• SARS-CoV-2 Pandemic 100%
• Sepsis 33%
• Severe COVID-19 33%
• Supplemental Therapy 33%
• Therapeutic Method 33%
• Thromboembolic Complications 33%
• Thrombosis 33%
• Tocilizumab 33%
• Vaccination 33%
• Vitamin Supplementation 33%
• Wider Population 33%

Medicine and Dentistry

• Acute Respiratory Distress Syndrome 25%
• Anakinra 25%
• Anticoagulant Therapy 25%
• Antiinflammatory Agent 25%
• Antimicrobial Therapy 25%
• COVID-19 50%
• COVID-19 Therapy 100%
• Cytokine 25%
• Cytokine Storm 25%
• Eculizumab 25%
• Fulminant 25%
• Hydroxychloroquine 25%
• Immune Response 50%
• Immunoglobulin G1 25%
• Immunomodulating Agent 25%
• Infection 25%
• Monoclonal Antibody 25%
• Multiple Organ Dysfunction Syndrome 25%
• Remdesivir 25%
• Sepsis 25%
• Serositis 25%
• Severe Acute Respiratory Syndrome Coronavirus 2 100%
• Thromboembolism 25%
• Thrombosis 25%
• Tocilizumab 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Adult Respiratory Distress Syndrome 25%
• Anakinra 25%
• Anticoagulant Agent 25%
• Antiinflammatory Agent 25%
• Antimicrobial Therapy 25%
• Cytokine 25%
• Cytokine Storm 25%
• Eculizumab 25%
• Hydroxychloroquine 25%
• Immunoglobulin G1 25%
• Immunomodulating Agent 25%
• Infection 25%
• Inflammation 25%
• Monoclonal Antibody 25%
• Multiple Organ Failure 25%
• Remdesivir 25%
• SARS Coronavirus 100%
• Sepsis 25%
• Thromboembolism 25%
• Thrombosis 25%
• Tocilizumab 25%